openPR Logo
Press release

Spinocerebellar Ataxias Pipeline Review 2024: Clinical Trials Update and Key Companies Involved by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma, Anima Biotech Inc

10-21-2024 03:50 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Spinocerebellar Ataxias Pipeline Review 2024: Clinical Trials

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 10+ key companies continuously working towards developing 12+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Spinocerebellar Ataxias Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/spinocerebellar-ataxias-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market.

The Spinocerebellar Ataxias Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Spinocerebellar Ataxias Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Spinocerebellar Ataxias treatment therapies with a considerable amount of success over the years.

*
Spinocerebellar Ataxias companies working in the treatment market are PTC Therapeutics, Minoryx Therapeutics, Design Therapeutics, RETROTOPE, Wave Life Sciences, VICO Therapeutics, BioGene, Steminent Biotherapeutics, Seelos Therapeutics, Biohaven Pharmaceuticals, and others, are developing therapies for the Spinocerebellar Ataxias treatment

*
Emerging Spinocerebellar Ataxias therapies in the different phases of clinical trials are- Vatiquinone, Leriglitazone, DT-216, RT011, ATXN3, VO659, BIIB132, Stemchymal, Trehalose, Troriluzole, and others are expected to have a significant impact on the Spinocerebellar Ataxias market in the coming years.

*
In September 2024, Biohaven Ltd. (NYSE: BHVN) announced that it will hold a conference call to discuss the topline results from Study BHV4157-206-RWE (NCT06529146). This study, developed in collaboration with the U.S. Food and Drug Administration (FDA), is focused on evaluating the effectiveness of troriluzole in treating Spinocerebellar Ataxia.

Spinocerebellar Ataxias Overview

The lack of voluntary muscle coordination and control over movement, known as ataxia, affects speech, eye movement, and gait stability. Spinocerebellar ataxia (SCA) is a neurological, diverse, progressive, inherited (autosomal dominant) illness that mostly affects the cerebellum.

Get a Free Sample PDF Report to know more about Spinocerebellar Ataxias Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/spinocerebellar-ataxias-pipeline-insight [https://www.delveinsight.com/report-store/spinocerebellar-ataxias-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Spinocerebellar Ataxias Drugs Under Different Phases of Clinical Development Include:

*
Vatiquinone: PTC Therapeutics

*
Leriglitazone: Minoryx Therapeutics

*
DT-216: Design Therapeutics

*
RT011: RETROTOPE

*
ATXN3: Wave Life Sciences

*
VO659: VICO Therapeutics

*
BIIB132: BioGene

*
Stemchymal: Steminent Biotherapeutics

*
Trehalose: Seelos Therapeutics

*
Troriluzole: Biohaven Pharmaceuticals

Spinocerebellar Ataxias Route of Administration

Spinocerebellar Ataxias pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Intranasal

*
Intrathecal

*
Intravenous

*
Oral

*
Oral/Intravenous

*
Parenteral

*
Subcutaneous

*
Subcutaneous/Intramuscular

*
Transdermal

Spinocerebellar Ataxias Molecule Type

Spinocerebellar Ataxias Products have been categorized under various Molecule types, such as

*
Antisense oligonucleotide

*
Gene therapy

*
Hormones

*
Neuropeptides

*
Oligonucleotides

*
Small Molecule

*
Triglyceride

Spinocerebellar Ataxias Pipeline Therapeutics Assessment

*
Spinocerebellar Ataxias Assessment by Product Type

*
Spinocerebellar Ataxias By Stage and Product Type

*
Spinocerebellar Ataxias Assessment by Route of Administration

*
Spinocerebellar Ataxias By Stage and Route of Administration

*
Spinocerebellar Ataxias Assessment by Molecule Type

*
Spinocerebellar Ataxias by Stage and Molecule Type

DelveInsight's Spinocerebellar Ataxias Report covers around 15+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Spinocerebellar Ataxias product details are provided in the report. Download the Spinocerebellar Ataxias pipeline report to learn more about the emerging Spinocerebellar Ataxias therapies [https://www.delveinsight.com/sample-request/spinocerebellar-ataxias-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Spinocerebellar Ataxias Therapeutics Market include:

Key companies developing therapies for Spinocerebellar Ataxias are - Biogen Inc, BioXcel Corp, Celavie Biosciences LLC, Ionis Pharmaceuticals Inc, Anima Biotech Inc, Biohaven Pharmaceutical Holding Company Ltd, Blade Therapeutics Inc, Seelos Therapeutics Inc., Steminent Biotherapeutics Inc, Annji Pharmaceutical Co Ltd, and others.

Spinocerebellar Ataxias Pipeline Analysis:

The Spinocerebellar Ataxias pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Spinocerebellar Ataxias with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spinocerebellar Ataxias Treatment.

*
Spinocerebellar Ataxias key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Spinocerebellar Ataxias Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spinocerebellar Ataxias market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Spinocerebellar Ataxias drugs and therapies [https://www.delveinsight.com/sample-request/spinocerebellar-ataxias-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Spinocerebellar Ataxias Pipeline Market Drivers

*
Increase in R&D activities for development of new drugs, innovations in clinical trial design are some of the important factors that are fueling the Spinocerebellar Ataxias Market.

Spinocerebellar Ataxias Pipeline Market Barriers

*
However, high cost associated with the treatment of spinocerebellar ataxia and other factors are creating obstacles in the Spinocerebellar Ataxias Market growth.

Scope of Spinocerebellar Ataxias Pipeline Drug Insight

*
Coverage: Global

*
Key Spinocerebellar Ataxias Companies: PTC Therapeutics, Minoryx Therapeutics, Design Therapeutics, RETROTOPE, Wave Life Sciences, VICO Therapeutics, BioGene, Steminent Biotherapeutics, Seelos Therapeutics, Biohaven Pharmaceuticals, and others

*
Key Spinocerebellar Ataxias Therapies: Vatiquinone, Leriglitazone, DT-216, RT011, ATXN3, VO659, BIIB132, Stemchymal, Trehalose, Troriluzole, and others

*
Spinocerebellar Ataxias Therapeutic Assessment: Spinocerebellar Ataxias current marketed and Spinocerebellar Ataxias emerging therapies

*
Spinocerebellar Ataxias Market Dynamics: Spinocerebellar Ataxias market drivers and Spinocerebellar Ataxias market barriers

Request for Sample PDF Report for Spinocerebellar Ataxias Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/spinocerebellar-ataxias-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Spinocerebellar Ataxias Report Introduction

2. Spinocerebellar Ataxias Executive Summary

3. Spinocerebellar Ataxias Overview

4. Spinocerebellar Ataxias- Analytical Perspective In-depth Commercial Assessment

5. Spinocerebellar Ataxias Pipeline Therapeutics

6. Spinocerebellar Ataxias Late Stage Products (Phase II/III)

7. Spinocerebellar Ataxias Mid Stage Products (Phase II)

8. Spinocerebellar Ataxias Early Stage Products (Phase I)

9. Spinocerebellar Ataxias Preclinical Stage Products

10. Spinocerebellar Ataxias Therapeutics Assessment

11. Spinocerebellar Ataxias Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Spinocerebellar Ataxias Key Companies

14. Spinocerebellar Ataxias Key Products

15. Spinocerebellar Ataxias Unmet Needs

16 . Spinocerebellar Ataxias Market Drivers and Barriers

17. Spinocerebellar Ataxias Future Perspectives and Conclusion

18. Spinocerebellar Ataxias Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=spinocerebellar-ataxias-pipeline-review-2024-clinical-trials-update-and-key-companies-involved-by-delveinsight-biogen-inc-bioxcel-corp-celavie-biosciences-ionis-pharma-anima-biotech-inc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Spinocerebellar Ataxias Pipeline Review 2024: Clinical Trials Update and Key Companies Involved by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma, Anima Biotech Inc here

News-ID: 3702768 • Views:

More Releases from ABNewswire

Phinity Therapy Strengthens Counselling Services in Edgbaston, Sparkhill & Northfield as Demand Grows Across Birmingham, UK
Phinity Therapy Strengthens Counselling Services in Edgbaston, Sparkhill & North …
Phinity Therapy has expanded its counselling services across Edgbaston, Sparkhill, and Northfield to meet growing mental health needs in Birmingham, UK. With more residents searching for "counselling near me", the clinic now offers greater access to qualified counsellors and evidence-based therapy. Phinity Therapy continues to support local communities with compassionate, personalised care and deep knowledge of Birmingham's diverse neighbourhoods. As Birmingham continues to evolve, so do the emotional and psychological challenges
JCFLOW Launches New Silicone Beads and Expands Wholesale Market Reach
JCFLOW Launches New Silicone Beads and Expands Wholesale Market Reach
JCFLOW [https://jcflowbeads.com/], a leading silicone bead factory store with operations in Las Vegas and China, is excited to announce the launch of its newest range of silicone beads, designed to meet the evolving needs of DIY crafters, small businesses, and creative entrepreneurs worldwide. Alongside the product launch, JCFLOW is implementing a strategic market expansion initiative to increase accessibility, offer customization options, and strengthen its position as a global leader in
Aspen Artist Shelly Hamill Celebrates 25 Years of Transforming Heirloom China Into Contemporary Mosaic Art
Aspen Artist Shelly Hamill Celebrates 25 Years of Transforming Heirloom China In …
Renowned mosaic artist Shelly Hamill marks over 25 years of creating unique sculptures from recycled china, offering collectors a meaningful way to transform family heirlooms into displayable art. Trained as a Master of Mosaic in portraiture at the prestigious Orsoni studio in Venice, Italy, Hamill now expands her offerings with a new print-on-demand service and an innovative Print of the Month Club. Shelly Hamill has spent more than a quarter century
Earned Everyday: Military Veterans Launch Athletic Brand Teaching Youth That Confidence Comes From Hard Work
Earned Everyday: Military Veterans Launch Athletic Brand Teaching Youth That Con …
Husband-and-wife Veteran team Matthew and Crystal Rorebeck have transformed their military experience and parenting journey into Earned Everyday, a Weatherford/Aledo athletic apparel brand with a powerful message for young athletes. Drawing from 46 combined years of military service and raising six children through deployment cycles, the retired Majors created a brand that teaches resilience, dedication, and the value of earning success. A new athletic apparel brand with deep roots in military

All 5 Releases


More Releases for Spinocerebellar

Spinocerebellar Ataxia (SCA) Market to Reach USD 2.1 Billion by 2034
Spinocerebellar ataxia (SCA) refers to a group of rare, inherited neurodegenerative disorders characterized by progressive loss of coordination, balance, and motor control due to cerebellar and spinal cord dysfunction. With more than 40 genetic subtypes identified (SCA1-SCA48), these disorders are typically autosomal dominant and present in adolescence or adulthood. Symptoms worsen over time, leading to gait instability, slurred speech, tremors, and, in advanced cases, severe disability. Download Full PDF Sample Copy
Spinocerebellar Ataxias (SCA) Market reaching approximately USD 2.6 billion by 2 …
Spinocerebellar ataxias (SCAs) are a group of rare, inherited neurodegenerative disorders characterized by progressive problems with movement, balance, and coordination. Caused by genetic mutations that affect the cerebellum and sometimes other parts of the nervous system, SCAs are classified into multiple subtypes (such as SCA1, SCA2, SCA3, and others), each with distinct genetic and clinical features. Patients often experience gait instability, slurred speech, vision problems, and difficulty with fine motor skills,
Spinocerebellar Ataxia Market Analysis: Opportunities & Forecast 2024-2031
Spinocerebellar Ataxia Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an
Spinocerebellar Ataxias Market Value Strategic Analysis | Biohaven Pharmaceutica …
According to HTF Market Intelligence, the Spinocerebellar Ataxias market to witness a CAGR of xx% during the forecast period (2024-2030). The Latest published a market study on Global Spinocerebellar Ataxias Market provides an overview of the current market dynamics in the Global Spinocerebellar Ataxias space, as well as what our survey respondents- all outsourcing decision-makers- predict the market will look like in 2030. The study breaks the market by revenue
G7 Spinocerebellar Ataxia Market 2024 Projections, Trends and Forecast 2024 - Da …
A new Report by DataM Intelligence, titled "G7 Spinocerebellar Ataxia Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031,"" offers a comprehensive analysis of the industry, which comprises insights on the G7 Spinocerebellar Ataxia market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market. This report has a complete table of contents, figures, tables, and charts, as well as insightful analysis. The G7 Spinocerebellar
Spinocerebellar Ataxia Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Spinocerebellar Ataxia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Spinocerebellar Ataxia, historical and forecasted epidemiology as well as the Spinocerebellar Ataxia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Spinocerebellar Ataxia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Spinocerebellar Ataxia market size